Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.960
-0.020 (-1.01%)
Nov 21, 2024, 1:11 PM EST - Market open
Inhibikase Therapeutics Employees
As of December 31, 2023, Inhibikase Therapeutics had 9 total employees, including 8 full-time and 1 part-time employees. The number of employees increased by 2 or 28.57% compared to the previous year.
Employees
9
Change (1Y)
2
Growth (1Y)
28.57%
Revenue / Employee
$0
Profits / Employee
-$2,173,917
Market Cap
131.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | 2 | 28.57% |
| Dec 31, 2022 | 7 | 0 | - |
| Dec 31, 2021 | 7 | 4 | 133.33% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 185 |
| Cabaletta Bio | 103 |
| PepGen | 64 |
| Acumen Pharmaceuticals | 52 |
| Candel Therapeutics | 42 |
| Cardiff Oncology | 32 |
| Zentek | 24 |
| Avalo Therapeutics | 19 |
IKT News
- 1 day ago - Inhibikase: Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha
- 7 days ago - Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - GlobeNewsWire
- 4 weeks ago - Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension - GlobeNewsWire
- 6 weeks ago - Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension - GlobeNewsWire
- 3 months ago - Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity - GlobeNewsWire
- 3 months ago - Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease - GlobeNewsWire